A Ludwig Cancer Research study has identified a specific mode of fat uptake by immune cells within tumors that serves as a ...

After issues at a third-party manufacturer caused the FDA to reject Regeneron's multiple myeloma bispecific antibody ...

But so far, so good for the TROP2-directed treatment, which is off to a "smooth market launch,” according to Daiichi CEO ...

Despite past setbacks, Zymeworks' partnerships, potential milestones, and large target markets present significant upside ...

Lotte Biologics, the biotech arm of Lotte Group, said on Thursday it has signed a deal with an Asia-based biotech company for ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced ...

Abnormal kinase signaling can promote other harmful traits, such as neuroinflammation and neuronal cell death. On the other ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Zymeworks presents six posters at AACR highlighting advancements in antibody-drug conjugates and T cell ... including its Annual Report on Form 10-K for its year ended December 31, 2024 (a copy ...

A new combination therapy has been found to give better results for patients with a certain type of colorectal cancer that no ...

From a meeting that celebrates basic research and being "first," a look at 3 data sets on therapies that would break new ...

A novel combination therapy offers better outcomes for patients with KRAS G12C metastatic colorectal cancer that have stopped ...